You are adding an alert for:
The use of intravitreal bevacizumab in the initial treatment of diabetic macular edema (DME) in a resident lead clinic in a county hospital, and comparative cost saving compared to other anti VEGF therapies.
You will receive an email whenever this article is corrected, updated, or cited in the literature. You can manage this and all other alerts in My Account
The alert will be sent to: